General rightsCopyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.• Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.• You may not further distribute the material or use it for any profit-making activity or commercial gain.• You may freely distribute the URL identifying the publication in the public portal. Accepted ArticleThis article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1111/bjd.15648 This article is protected by copyright. All rights reserved. This is the peer reviewed version of the following article: 'Recommendation to test limonene hydroperoxides 0.3% and linalool hydroperoxides 1.0% in the British Baseline patch test series', British Journal of Dermatology, which has been published in final form at http://dx.doi.org/10.1111/bjd.15648. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving. Accepted ArticleThis article is protected by copyright. All rights reserved. Accepted ArticleThis article is protected by copyright. All rights reserved. ABSTRACT Background:There is a significant rate of sensitisation worldwide to the oxidised fragrance terpenes limonene and linalool. Patch testing to oxidised terpenes is not routinely carried out; the ideal patch test concentration is unknown.

The efficacy and safety of calcipotriol solution in the treatment of scalp psoriasis was compared with placebo (vehicle solution), in a multicentre double-blind, randomized, parallel-group study of 49 adult patients. Calcipotriol solution (50 micrograms/ml), or placebo, was applied twice daily over a 4-week period. At the end of the study period 60% of patients on calcipotriol showed clearance or marked improvement of their psoriasis compared with 17% on placebo. Overall assessment of treatment response showed that calcipotriol was superior to placebo in both investigator (P < 0.001; 95% confidence interval for difference 19.0-67.6) and patient (P < 0.001; 95% confidence interval for difference 18.3-68.0) assessments. Total sign score for psoriasis (i.e. the sum of the scores for redness, thickness and scaliness) decreased by 48.9% in the calcipotriol group, and by 18.6% in the placebo group (P = 0.005). Calcipotriol was significantly superior to placebo in reducing redness, thickness, scaliness and extent of psoriasis, and in the patients' assessment in reducing scalp flaking and itching. No statistically significant changes in blood biochemistry were detected during the study, and the solution was generally well tolerated.

In general, BCCs are managed according to BAD guidelines in Scotland, but waiting times vary considerably.

Table 1). Some limitations need to be considered when interpreting the findings of the present study. Firstly, the cross-sectional design precluded the ability to make inferences about causality. Secondly, the small sample size precluded multivariable analyses, and the lack of a control group limited us from making any comparison with other dermatological disorders. The sample size was heterogeneous in terms of smoking habits, which could have affected our results. However, a major strength of our study is that we studied a sample of patients with HS with diverse geographical origins. As previously mentioned, beliefs about stigmatization differ throughout various parts of the world, but stigmatization is generally an important concern for many dermatological patients. 6 Our data show that perceived stigmatization is common in patients with HS and not limited by geographical origin, indicating that HS stigmatization is a global issue.Ongoing perceptions of stigmatization may contribute to difficulty coping with the disease, and exacerbate negative emotions and maladaptive thought processes, in turn leading to negative psychological outcomes and impaired quality of life, as seen in our results. In fact, it may be hypothesized that stigma is a key factor in the association between HS and psychological comorbidities.

This paper reports on a case of Orofacial Granulomatosis (OFG) in which the presence of amalgam fillings appears to have played a part in the aetiology. Once these restorations were removed and replaced with an alternative composite restorative material, all symptoms and signs of OFG resolved completely. This case highlights the necessity to include dental metals in the patch test battery when performing delayed patch testing on patients with OFG.